Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac

BACKGROUND: Currently, booster dose is needed after 2 doses of non-live COVID-19 vaccine. With limited resources and shortage of COVID-19 vaccines, intradermal(ID) administration might be a potential dose-sparing strategy. OBJECTIVE: To determine immunologic response and reactogenicity of ID ChAdOx1...

Descripción completa

Detalles Bibliográficos
Autores principales: Nantanee, Rapisa, Aikphaibul, Puneyavee, Jaru-Ampornpan, Peera, Sodsai, Pimpayao, Himananto, Orawan, Theerawit, Tuangtip, Sophonphan, Jiratchaya, Tovichayathamrong, Punyot, Manothummetha, Kasama, Laohasereekul, Tysdi, Hiransuthikul, Narin, Hirankarn, Nattiya, Puthanakit, Thanyawee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058819/
https://www.ncbi.nlm.nih.gov/pubmed/35513961
http://dx.doi.org/10.1016/j.vaccine.2022.04.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058819/
https://www.ncbi.nlm.nih.gov/pubmed/35513961
http://dx.doi.org/10.1016/j.vaccine.2022.04.067

Ejemplares similares